Matthew J. Matasar, MD, Discusses Unmet Needs in Relapsed Indolent Non-Hodgkin Lymphoma

The lymphoma expert discussed how the addition of copanlisib to rituximab may add another treatment option for patients with relapsed indolent B-cell lymphomas.

Patients with indolent B-cell lymphomas tend to have disease relapses, highlighting the need for more treatment options in their armamentarium.

At the 2021 Virtual AACR Annual Meeting, Matthew J. Matasar, MD, presented data from the primary results of the phase 3 CHRONOS-3 study (NCT02367040), which demonstrated that use of the combination of copanlisib (Aliqopa) and rituximab (Rituxan) was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

In an interview with CancerNetwork®, Matasar, an associate member of the Lymphoma Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center, discussed the unmet needs for patients with indolent B-cell lymphomas.


Indolent B-cell lymphomas are collectively a set of illnesses whose nature is to be chronically relapsing. These are illnesses that are not typically considered curative with routine systemic therapies. Most patients will typically experience multiple lines of therapy over the course of their illness. Unfortunately, we really do, as a discipline, need a greater variety of more effective and less toxic therapies to offer our patients.

For patients with relapsed indolent lymphoma whose disease has remained sensitive to rituximab (Rituxan) monotherapy, [which] remains a standard treatment, responses to it are not as frequent as we would like, and the duration of response is not as long as we would like. There remains an interest in trying to find ways to improve upon that as a standard treatment. Prior attempts of combining a PI3K inhibitor with rituximab have been unsuccessful and are largely limited by toxicities, such as enteritis , pneumonitis, and hepatitis. Our hope is that copanlisib—which unlike other previously tested agents which have been oral, clinically administered PI3K inhibitors—given intravenously might be able to overcome those challenges and prove to be a safe and effective medicine when combined with rituxumab.


Matasar MJ, Capra M, Ozcan M, et al. CHRONOS-3: randomized phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL). Presented at: 2021 AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract CT001.

Related Videos
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.
Common symptoms following debulking surgery for gynecologic cancer appear to include pain, diarrhea, and nausea, according to an expert from Memorial Sloan Kettering Cancer Center.
Patients who use a recovery tracker tool appear to experience lower hospital readmission rates following gynecologic cancer debulking surgery compared with those who did not.
Medical oncologists and gynecologic oncologists alike have a shared responsibility to help treat symptoms of neuropathy in patients undergoing chemotherapy for gynecologic cancer, according to an expert from Duke University Medical Center.
Future research assessing cryocompression for those with gynecologic cancers will make use of different products to make the intervention easier and more accessible for patients.
Cryocompression demonstrates potential for preventing chemotherapy-induced neuropathy for those with gynecologic cancers, according to an expert from Duke University Medical Center.